BK

Benjamin Klapholz

Principal Scientist | Cell Therapy Innovation - Technology Development at bit.bio

Benjamin Klapholz has extensive work experience in the field of cell engineering, technology development, and molecular biology. Benjamin is currently a Group Leader at bit.bio, where they are responsible for leading the Cell Engineering & Technology Development team. Prior to this, they held the role of Group Leader at bit.bio, focusing on Technology Development.

Before joining bit.bio, Benjamin worked as a Principal Scientist at Empyrean Therapeutics, where they contributed to scientific research and development. Benjamin also held positions at Horizon Discovery as a Senior Scientist, contributing to various research projects. Benjamin also worked as a Visiting Scientist at the MRC Laboratory of Molecular Biology (LMB).

Benjamin's work experience began at the University of Cambridge, where they worked as a Postdoctoral Research Associate. During this time, they conducted research on talin, a protein crucial for cell-matrix adhesion. Benjamin'sresearch findings were published in a major peer-reviewed journal and frequently cited at conferences.

Prior to their postdoctoral position, Benjamin was a PhD student at Institut Curie. Benjamin'sresearch focused on the function of the Chromatin Assembly Factor-1 (CAF-1) in Drosophila. Benjamin also completed a Master's degree during their time at Institut Curie, where they gained experience in various molecular biology techniques.

Overall, Benjamin Klapholz has a diverse and extensive background in cell engineering, technology development, and molecular biology, with a strong focus on research and development.

Benjamin Klapholz started their education journey in 1999 at Université Paul Sabatier Toulouse III, where they pursued a degree in Biology. Benjamin completed their Maitrise degree in Biology in 2003. Following that, in 2003, they enrolled at UVSQ Université de Versailles Saint-Quentin-en-Yvelines for a DEA degree in Genetics, which they finished in 2004. Benjamin's academic pursuits continued, and from 2004 to 2008, they attended Pierre and Marie Curie University, where they obtained a PhD in Biology.

Links

Previous companies

University of Cambridge logo
Horizon Discovery logo

Timeline

  • Principal Scientist | Cell Therapy Innovation - Technology Development

    October 1, 2023 - present

  • Group Leader | Cell Engineering & Technology Development

    January 1, 2023

  • Group Leader - Technology Development

    July, 2020